The use of direct oral anticoagulants in subgroups of patients with specific characteristics

Sergey R. Gilyarevsky , Maria V. Golshmid , Nana G. Bendeliani , Irina M. Kuzmina

For citation:

Abstract

The paper is focused on the issues of using direct oral anticoagulants (DOACs) in the subgroups of patients with specific characteristics. The current data on the effects of DOACs in such patients during anticoagulant therapy aimed at prevention of thromboembolic complications in both patients with atrial fibrillation (AF) and venous thromboembolic complications (VTECs) are provided. Insufficient knowledge of the DOAC effects in such populations of patients, i.e. in very old people, people with kidney disease and obese patients, that results from the small number of patients with similar characteristics included in the large-scale randomized clinical trials, is noted. The paper discusses the pharmacological features of using DOACs in patients with the listed above characteristics and possible changes in clinical efficacy and safety of DOACs used in clinical practice separately. The data on three DOACs available in Russia, apixaban, rivaroxaban and dabigatran, are provided. The data of the clinical trial analysis provided in the paper make it possible to generally assume the appropriateness of using DOACs for treatment and prevention of VTECs in patients with pronounced obesity, as well as the advantages of apixaban over other DOACs in patients with AF and concomitant obesity. The issues of using DOACs in patients with kidney disease are considered. The scarcity of evidence-based information about patients with pronounced kidney dysfunction is noted. The provided data on the effects of DOACs in very old people show the advantages of taking apixaban in this population of patients with AF, based primarily on safety indicators.

Keywords: direct oral anticoagulants,special patient groups, apixaban, rivaroxaban, dabigatran, obesity, kidney dysfunction, old age

References

1. Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol 2019; 42 (8): 774–82. DOI: 10.1002/clc.23196
2. Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10): 883–91. DOI: 10.1056/NEJMoa1009638
3. Bauersachs R, Berkowitz SD, Brenner B et al.; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26): 2499–510. DOI: 10.1056/NEJMoa1007903
4. Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11): 981–92. DOI: 10.1056/NEJMoa1107039
5. Agnelli G, Buller HR, Cohen A et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9): 799–808. DOI: 10.1056/NEJMoa1302507
6. Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12): 1139–51. DOI: 10.1056/NEJMoa0905561
7. Lauw MN, Eikelboom JW, Coppens M et al. Effects of dabigatran according to age in atrial fibrillation. Heart 2017; 103 (13): 1015–23. DOI: 10.1136/heartjnl-2016-310358
8. Schulman S, Kearon C, Kakkar AK et al.; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (8): 709–18. DOI: 10.1056/NEJMoa1113697
9. Giugliano RP, Ruff CT, Braunwald E et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22): 2093–104. DOI: 10.1056/NEJMoa1310907
10. Boriani G, Ruff CT, Kuder JF et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thromb Haemost 2021; 121 (2): 140–9. DOI: 10.1055/s-0040-1716540
11. Büller HR, Décousus H, Grosso MA et al.; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15): 1406–15. DOI: 10.1056/NEJMoa1306638
12. Martin K, Beyer-Westendorf J, Davidson BL et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (6): 1308–13. DOI: 10.1111/jth.13323
13. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47 (2): 218–26. DOI: 10.1177/0091270006296058
14. Huxley RR, Lopez FL, Folsom AR et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123 (14): 1501–8. DOI: 10.1161/CIRCULATIONAHA.110.009035
15. Kushnir M, Choi Y, Eisenberg R et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 2019; 6 (7): e359–e365. DOI: 10.1016/S2352-3026(19)30086-9
16. Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Pharmacotherapy 2020; 40 (3): 204–10. DOI: 10.1002/phar.2369
17. Kido K, Ngorsuraches S. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. Ann Pharmacother 2019; 53 (2): 165–70. DOI: 10.1177/1060028018796604
18. Lip GYH, Keshishian A, Li X et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49 (12): 2933–44. DOI: 10.1161/STROKEAHA.118.020232
19. Deitelzweig S, Keshishian A, Kang A et al. Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J Clin Med 2020; 9 (6): 1633. DOI: 10.3390/jcm906163.
20. Netley J, Howard K, Wilson W. Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review. J Thromb Thrombolysis 2019; 48 (3): 359–65. DOI: 10.1007/s11239-019-01857-2
21. Nolin TD. A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. Semin Dial 2015; 28 (4): 325–9. DOI: 10.1111/sdi.12374
22. Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug Metab Pharmacokinet 2019; 44 (1): 1–12. DOI: 10.1007/s13318-018-0501-y
23. Soliman EZ, Prineas RJ, Go AS et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102–7. DOI:10.1016/j.ahj.2010.03.027
24. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098–106. DOI:10.1038/ki.2009.477
25. Zimmerman D, Sood MM, Rigatto C et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 3816-22. DOI: 10.1093/ndt/gfs416
26. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 2022; 12 (1): 7–11. DOI: 10.1016/j.kisu.2021.11.003
27. Herndon K, Guidry TJ, Wassell K, Elliott W. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital. Ann Pharmacother 2020; 54 (6): 554–60. DOI: 10.1177/1060028019897053
28. Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease. Ann Pharmacother 2018; 52 (11): 1078–84. DOI: 10.1177/1060028018781853
29. Sarratt SC, Nesbit R, Moye R. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease. Ann Pharmacother 2017; 51 (6): 445–50. DOI: 10.1177/1060028017694654
30. Hanni C, Petrovitch E, Ali M et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv 2020; 4 (11): 2366–71. DOI: 10.1182/bloodadvances.2019000972
31. Gaertner S, Cordeanu EM, Nouri S et al. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes. Int J Cardiol 2017; 226: 103–9. DOI: 10.1016/j.ijcard.2016.10.045
32. White EM, Coons JC. Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure. Curr Cardiol Rep 2021; 23 (4): 27. DOI: 10.1007/s11886-021-01456-9. PMID: 33655373.
33. Su X, Yan B, Wang L et al. Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. Am J Kidney Dis 2021; 78 (5): 678–89.e1. DOI: 10.1053/j.ajkd.2021.02.328
34. Hindricks G, Potpara T, Dagres N et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (5): 373–498. DOI: 10.1093/eurheartj/ehaa612
35. Poli D, Antonucci E, Bertù L et al.; coordinator of START2 Register. Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. Thromb Res 2019; 183: 28–32. DOI: 10.1016/j.thromres.2019.08.024
36. Lafaie L, Célarier T, Monreal M et al. The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. Expert Opin Drug Metab Toxicol 2022; 18 (1): 27–37. DOI: 10.1080/17425255.2022.2045273
37. Giugliano RP. Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. Eur Heart J Suppl 2022; 24 (Suppl. A): A1–A10. DOI: 10.1093/eurheartj/suab150
38. Patti G, Lucerna M, Pecen L et al. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc 2017; 6 (7): e005657. DOI: 10.1161/JAHA.117.005657
39. Polymeris AA, Macha K, Paciaroni M et al.; NOACISP-LONGTERM, Erlangen Registry, CROMIS-2, RAF, RAF-DOAC, SAMURAI-NVAF and Verona Registry Collaborators. Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. Ann Neurol 2022; 91 (1): 78–88. DOI: 10.1002/ana.26267
40. Raposeiras-Roubín S, Alonso Rodríguez D, Camacho Freire SJ et al. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. J Am Med Dir Assoc 2020; 21 (3): 367–73.e1. DOI: 10.1016/j.jamda.2019.08.033
41. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35 (28): 1864–72. DOI: 10.1093/eurheartj/ehu046
42. Lobraico-Fernandez J, Baksh S, Nemec E. Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies. Drugs R D 2019; 19 (3): 235–45. DOI: 10.1007/s40268-019-0275-y
43. Pazan F, Collins R, Gil VM et al. A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs Aging 2020; 37 (7): 539–48. DOI: 10.1007/s40266-020-00771-0

For citation:Gilyarevsky S.R., Golshmid M.V., Bendeliani N.G., Kuzmina I.M. The use of direct oral anticoagulants in subgroups of patients with specific characteristics. Clinical review for general practice. 2022; 3. DOI: 10.47407/kr2022.3.3.0012091p

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice